Constraints on antidepressant prescribing and principles of cost- effective antidepressant use Part 1: Depression and its treatment

PharmacoEconomics

Volumn 11, Issue 5, 1997, Pages 419-443

  Henry, John A ^a   Rivas, Carol A ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

COST EFFECTIVENESS ANALYSIS; DEPRESSION; DRUG COST; DRUG FORMULARY; DRUG USE; HEALTH CARE COST; HUMAN; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SUICIDE;

EID: 0030910416     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199711050-00005     Document Type: Review

References (208)

1. Montgomery SA, Bebbington P, Cowen P, et al. Guidelines for treating depressive illness with antidepressants. J Psychopharmacol 1993; 7 (1): 19-23
2. Regier DA, Hirschfeld RMA, Goodwin FK, et al. The NIMH depression awareness, recognition and treatment program: structure, aims and scientific basis. Am J Psychiatry 1988; 145: 1351-7
3. Kind P, Sorensen J. The costs of depression. Int Clin Psychopharmacol 1993; 7: 191-5
4. Henry JA. Debits and credits in the management of depression. Br J Psychiatry 1993; 163 (20 Suppl.): 33-9
5. Hagnell O, editor. The incidence of mental illness over a quarter of a century. The Lundby longitudinal study of mental illness in a tolal population based on 42,000 observation years. Stockholm: Almkvist and Wiksell, 1990
6. Jablensky A. Prediction of the course and outcome of depression. Psychol Med 1987; 17: 1-9
7. Blacker CV, Clare AW. Depressive disorder in primary care. Br J Psychiatry; 150: 737-51
8. Katon W, Roy-Byrne PP. Antidepressants in the medically ill: diagnosis and treatment in primary care. Clin Chem 1988: 34 (5): 829-36
9. Stoudemire A, Frank R, Hedemark N, et al. The economic burden of depression. Gen Hosp Psychiatry 1986; 8: 387-94
10. Gold PW, Goldwin FK, Chrousos GP. Clinical and biochemical manifestations of depression: relation to the neurobiology of stress. N Engl J Med 1988; 319: 348-53
11. Wells KB, Stewart A, Hayes RD, et al. The functioning and well-being of depressed patients: results from the medical outcome study. JAMA 1989; 262 (7): 914-19
12. Broadhead WE, Blazer DG, George LK, et al. Depression, disability days and days lost from work in a prospective epidemiologic study. JAMA 1990; 264: 2524-8
13. Kaum W, Von Korff M, Lin E, et al. Distressed high utilizers of medical care: DSM-III-R diagnoses and treatment needs. Gen Hosp Psychiatry 1990; 12: 355-62
14. Wells KB, Golding JM, Burnam MA. Psychiatric disorder and limitations in physical functioning in a sample of the Los Angeles general population. Am J Psychiatry 1988; 145: 712-7
15. Bridges K, Goldberg D. Somatic presentation of DSM-III psychiatric disorder in primary care. J Psychiatr Res 1985; 29: 563-9
16. Bridges K, Goldberg D. Somatic presentation of depressive illness in primary care. In: Freeling P, Downey LJ, Malkin JC, editors. The presentation of depression: current approaches. London: Royal College of General Practitioners, 1987
17. Goldberg D, Huxley P. Common mental disorders: a bio-social model. London: Routledge, 1992
18. von Korff M, Ormel J, Katon W, et al. Disability and depression among high utilizers of health care. Arch Gen Psychiatry 1992; 49: 91-100
19. Weissman MM, Leaf PJ, Tischler GL, et al. Affective disorders in five United States communities. Psychol Med 1988; 18 (1): 141-53
20. Weissman MM, Myers JK. Affective disorders in a US urban community: the use of research diagnostic criteria in an epidemiological survey. Arch Gen Psychiatry 1978; 35 (11): 1304-11
21. Jonsson B, Bebbington P. Economic studies of the treatment of depressive illness. In: Jonsson B, Rosenbaum J, editors. Health economics of depression. New York: John Wiley, 1993: 35-48
22. Jonsson B, Bebhington P. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry 1994; 164: 665-73
23. Coulehan JL, Schulberg HC, Block MR, et al. Medical comorbidity of major depressive disorder in a primary medical practice. Arch Intern Med 1990; 150 (11): 2363-7
24. Office of Population Censuses and Surveys. Series VS No 15. London: OPCS, 1990
25. Turner R. Quality of life: experience with sertraline. Int Clin Psychopharmacol 1994; 9: 27-31
26. Greenberg PE, Stiglin LE, Finkelstein SN, et al. The economic burden of depression in 1990. J Clin Psychiatry 1993; 54 (11): 405-18
27. Montgomery SA. Anxiety and depression. Petersfield: Wrightson Biomedical Publishing Ltd, 1990: 46, 59
28. Angst J, Vollrath M, Koch R. New aspects on epidemiology of depression. In: Angst J, Woggon B, editors. Lofepramine in the treatment of depressive disorders. Vieweg: Braunschweig, 1988: 1-14
29. Kocsis JH, Frances AJ, Voss C, et al. Imipramine treatment for chronic depression. Arch Gen Psychiatry 1988; 45: 253-7
30. Tsuang MT, Woolson JRF, Fleming JA. Premature deaths in schizophrenia and affective disorders. Arch Gen Psychiatry 1980; 37: 979-83
31. Guze SB, Robins E. Suicide and primary affective disorders. Am J Psychiatry 1970; 117: 437-8
32. Winokur G, Tsuang M. The Iowa 500: suicide in mania, depression and schizophrenia. Am J Psychiatry 1975; 132: 650-3
33. Barraclough BM, Bunch J, Nelson B, et al. A hundred cases of suicide: clinical aspects. Br J Psychiatry 1986; 125: 355-73
34. Paykel ES. The treatment of depression: the relevance of research for clinical practice. Br J Psychiatry 1989; 155: 754-63
35. Levenson JL, Hamer RM, Rossiter LF. A randomized controlled study of psychiatric consultation guided by screening in general medical inpatienls. Am J Psychiatry 1992; 149: 631-7
36. Kellerman AL, Rivara FP, Somes G, et al. Suicide in the home in relation to gun ownership. N Engl J Med 1992; 327: 467-72
37. Office of Population Censuses and Surveys, series DH4. Mortality statistics - accidents and violence (England and Wales). London: Her Majesty's Stationery Office 1990, 1991, 1992
38. Office of Population Censuses and Surveys, series DH2. Mortality statistics - accidents and violence (England and Wales). London: Her Majesty's Stationery Office, 1990, 1991, 1992, 1993
39. Goldstein RB, Black DW, Nasrallah A, et al. The prediction of suicide: sensitivity, specificity, and predictive value of a multivariate model applied to suicide among 1906 patients with affective disorders. Arch Gen Psychiatry 1991; 418: 418-22
40. Hawton K. Assessment of suicide risk. Br J Psychiatry 1987; 150: 145-53
41. Kreitman N. How useful is the prediction of suicide following parasuicide? In: Wilmotte J, Mendlewicz J, editors. New trends in suicide prevention. Basel: Karger, 1982
42. McNamee JE, Offord DR. Prevention of suicide. Can Med Assoc J 1990; 142: 1223-30
43. Motto JA. An integrated approach to estimating suicide risk. Suicide Life Threat Behav 1991; 21: 74-89
44. Winokur G, Black DW. Suicide - what can be done? N Engl J Med 1992; 327: 490-1
45. Nordentoft M, Breum L, Munck LK, et al. High mortality by natural and unnatural causes: a 10 year follow up study of patients admitted to a poisoning treatment centre after suicide attempts. BMJ 1993; 306: 1637-41
46. Murphy GE. Suicide and substance abuse. Arch Gen Psychiatry 1988; 45: 593-4
47. Prescott LF, Highley MS. Drugs prescribed for self poisoners. BMJ 1985; 290: 1633-6
48. Weissman MM, Klerman GL, Prusoff BA, et al. Depressed outpatients: results one year after treatment with drugs and/or interpersonal psychotherapy. Arch Gen Psychiatry 1981; 38: 51-5
49. Weissman MM. The psychological treatment of depression: update of clinical trials. In: Williams JBW, Spitzer RL, eds. Psychotherapy research: where are we and where should we go? New York: Guilford Press, 1984: 89-105
50. Gerner R, Estabrook W, Steuer J, et al. Treatment of geriatric depression with trazodone, imipramine and placebo: a double-blind study. J Clin Psychiatry 1980; 41: 216-220
51. Thompson C, Thompson CM. The prescribing of antidepressants in general practice II. A placebo-controlled trial of low-dose dothiepin. Hum Psychopharmacol 1989; 4: 191-204
52. West R, Depression. London: Office of Health Economics, 1992
53. Abraham IL, Bryant Neese J, Westerman PS. Depression: nursing implications of a clinical and social problem. Nurs Clin North Am 1991; 26 (3): 527-36
54. Feighner JP. A double-blind comparison of paroxetine, imipramine and placebo in depressed outpatients. In: Ashcroft GW, editor. Depression - a once in a lifetime event? Oxford: Clinical Neuroscience Publishers, 1991
55. Mendlewicz J. The social burden of depressive disorders. Neuropsychobiology 1989; 22: 178-80
56. Rice DP. Conceptual and estimation issues related to cost of illness studies [abstract]. The Second Workshop of Cost and Assessment in Psychiatry: the costs of affective disorders. 1992 Oct 26-28: Venice
57. McGuire TG. Outcomes, costs and design of health insurance for depression. In: Jonsson B, Rosenbaum J, editors. Health economics of depression: perspectives in psychiatry, Vol 4, Chichester: Wiley, 1993: 77-96
58. Croft-Jeffreys C, Wilkinson G. Estimated costs of neurotic disorder in UK general practice 1985. Psychol Med 1989; 19: 549-58
59. Henzman P. The economic costs of mental illness in Sweden 1975. Acta Psychol (Scand) 1983; 68: 359-67
60. McCombs JS, Nichol MB. The cost of treatment failure. In: Jonsson B, Rosenbaum J, editors. Health economics of depression: perspectives in psychiatry, Vol 4. Chichester: Wiley, 1993: 49-64
61. Walinder J, Carlsson P, Rutz, W. The economic impact of an educational programme on diagnosis and treatment of depression in Sweden. In: Jonsson B, Rosenhaum J, editors. Health economics of depression: perspectives in depression, Vol 4. Chichester: Wiley, 1993: 97-110
62. Weiss KB, Gergen PJ, Hodgson TA. An economic evaluation of asthma in the United States. N Engl J Med 1992; 326: 862-6
63. Eisenberg JM, Glick H, Koffer H. Pharmacoeconomics: economic evaluation of pharmaceuticals. In: Strom BL, editor. Pharmacoepidemiology. New York: Churchill Livingstone, 1989: 325-50
64. Hartunian NS, Smart CN, Thompson MS. The incidence and economic costs of major health impairments. Lexinglon: Lexington Books, 1980
65. Weisbrod BA. Benefit-cost analysis of a controlled experiment treating the mentally ill. J Hum Resour 1981; 16: 523-48
66. Cooper BS, Rice DP. The economic cost of illness revisited. Soc Secur Bull 1976; 39: 21-36
67. Black DAK, Pole JD. Priorities in biomedical research: indices of burden. Br J Prevent Med 1975; 29 (4): 222-7
68. Weisbrod BA. Economics of mental illness: costs, benefits and incentives. In: Jonsson B, Rosenbaum J, editors. Health economics of depression: perspectives in psychiatry, Vol 4. Chichester: Wiley, 1993: 15-34
69. Rice DP, Kelman S, Miller LS. Estimates of economic costs of alcohol and drug abuse and mental illness, 1985 and 1988. Public Health Rep 1991; 106(3): 280-92
70. Drummond MF, Stodden GL, Torrence G. Methods for the economic evaluation of healthcare programmes. Oxford: Oxford Medical, 1987
71. von Korff M, Ormel J, Katon W, et al. Disability and depression among high utilizers of health care. Arch Gen Psychiatry 1992; 49: 91-100
72. Montgomery SA. Suicide and antidepressants. Drugs 1992; 43 Suppl: 24-31
73. Kiloh LG, Andrews G, Neilson M. The long-term outcome of depressive illness. Br J Psychiatry 1988; 153: 752-57
74. Bulik CM, Carpenter LL, Kupfer DJ, et al. Features associated with suicide attempts in recurrent major depression. J Affect Disord 1990; 18 (1): 29-37
75. Angst J, Stassen HH, Gross G, et al. Suicide in affective and schizoaffective disorders. In: Marneros A. Tsuang MT, editors. Affective and schizoaffective disorders. Berlin: Springer Verlag, 1990: 186-95
76. Weinstein MC, Saturno PJ. Economic impact of youth suicide and suicide atlempls. In: US DHSS Publication: 1982-1989. Rockville: Department of Health and Human Services, 1989: ADM 89-1264
77. Wells KB. Depression as a tracer condition for the national study of medical care outcomes: background review. Rand Corporation 1985: R-3293-RWJ/HJK
78. Eaton WW, Holzer CE III, von Korff M, et al. The design of the Epidemiological Catchment Area surveys: the control and measurement of error. Arch Gen Psychiatry 1984; 41: 942
79. Pettito JM, Folds JD, Ozer H, et al. Abnormal diurnal variation in circulating natural killer cell phenotypes and cytotoxic activity in major depression. Am J Psychiatry 1992; 149: 694-6
80. Robinson RG, Starr LB, Price TR. A two year longitudinal study of mood disorder following stroke: prevalence and duration at six months follow-up. Br J Psychiatry 1984; 144: 256-62
81. Babigian HM, Guttmacher LB. Epidemiologic considerations in electroconvulsive therapy. Arch Gen Psychiatry 1984; 41: 246-53
82. Rovner BW, German PS, Brant U, et al. Depression and mortality in nursing homes. JAMA 1991: 265 (8): 993-6
83. Goodwin GM. The effects of treatment on mortality in affective illness. J Psychopharmacol 1992; 6: 312-7
84. Thompson D, Pudney M. Mental illness: the fundamental facts. London: Mental Health Foundation, 1989
85. Jenkins R. Minor psychiatric morbidity in employed young men and women and its contribution to sickness absence. Br J Ind Med 1985; 42: 147-54
86. Angst J. Epidemiology of depression. Psychopharmacology (Berl) 1992; 106 Suppl.: 71S-4S
87. Bech P, Dunbar GC, Stoker MJ. The challenge of measuring quality of life in psychiatric patients. In: Jonsson B, Rosenbaum J, editors. Health economics of depression: perspectives in psychiatry. Vol 4. Chichester: Wiley, 1993: 111-28
88. Slevin ML, Plant H, Lynch D, et al. Who should measure quality of life, the doctor or the patient? Br J Cancer 1988; 57: 109-12
89. Olsen JA. Persons vs years: two ways of eliciting implicit weights. Health Econ 1994; 3: 39-46
90. Sackett DL, Torrance GW. The utility of different health states as perceived by the general public. J Chron Dis 1978; 31: 697-704
91. Kaplan RM, Anderson JP. A general health policy model: update and applications. J Health Serv Res 1988; 23: 203-35
92. Simon G, Wagner E, Von Korff M. Cost-effectiveness comparisons using 'real world' randomized trials: the case of new antidepressant drugs. J Clin Epidemiol 1995; 48: 363-73
93. O'Brien BJ, Novosel S, Torrance G, et al. Assessing the economic value of a new antidepressant: a willingness-to-pay approach. Pharmacoeconomics 1995; 8: 34-45
94. Toufexis A. The personality pill. Time 1993 Oct 11; 76-7
95. Lee AS, Murray RM. The long-term outcome of Maudsley depressives. Br J Psychiatry 1988; 153: 741-51
96. WHO Mental Health Collaborating Centres, 1989
97. Boyer WF, Feighner JP. In: Jonsson B, Rosenhaum J, editors. Health economics of depression: perspectives in psychiatry, Vol. 4. Chiehester: Wiley, 1993: 65-76
98. Mindham RH, Howland C, Shepherd M. Continuation therapy with tricyclic antidepressants in depressive illness. Lancet 1987; II: 854-55
99. Prien R, Kupfer D. Continuation drug therapy for major depressive episodes: how long should it be maintained? Am J Psychiatry 1986; 143: 18-23
100. Weissman MM, Klerman GL. Epidemiology of mental disorders: emerging trends in the United States. Arch Gen Psychiatry 1978; 35 (6): 705-12
101. Kupfer DJ, Frank E, Perel JM, et al. Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1992; 49: 769-73
102. Greden JF. Antidepressant maintenance medications: when to discontinue and how to stop. J Clin Psychiatry 1993; 54: 39-45
103. Old Age Depression Interest Group. How long should the elderly take antidepressants? Br J Psychiatry 1993; 162: 175-82
104. Prien RF, Klett CJ, Caffey EM. Lithium carbonate and imipramine in the prevention of affective episodes. Arch Gen Psychiatry 1973; 29: 420-25
105. Doogan DP, Caillard V. Sertraline in the prevention of depression. Br J Psychiatry 1992; 160: 217-22
106. Hirschfeld RMA, Goodwin FK. Mood disorders. In: Talbott JA, Yudowsky SC, editors. Textbook of psychiatry. Washington, DC: American Psychiatric Press, 1988
107. Baldessarini RJ. Current status of antidepressants: clinical pharmacology and therapy. J Clin Psychiatry 1989; 50: 117-26
108. McCombs JS, Nichol MB, Stimmel GL, et al. The cost of antidepressant drug therapy failure: a study of antidepressant use patterns in a Medicaid population. J Clin Psychiatry 1990; 51 (6): 60-72
109. Katon W, von Korff M, Lin E, et al. Adequacy and duration of antidepressant treatment in primary care. Med Care 1992; 30: 67-76
110. Berlanga C, Ortega-Soto HA. A 3-year follow-up of a group of treatment-resistant depressed patients with a MAOI/tricyclic combination. J Affect Disord 1995; 34: 187-92
111. Tiller J, Mitchell P, Burrows GD. Monoamine oxidase inhibitors (MAOI) or reversible inhibitors of monoamine oxidase (RIMA) tricyclic (TCA) combination therapy. Aust N Z J Psychiatry 1992; 26: 327-9
112. Grounds D. On combining TCAs and MAOIs. Aust N Z J Psychiatry 1993; 26: 327-9
113. Johnson FN. The evolution of lithium therapy. J Psychopharmacol 1992; 6: 325-9
114. Ballenger JC, Post RM. Carbamazepine in manic-depressive illness: a new treatment. Am J Psychiatry 1980; 137: 782-90
115. Robinson DS, Nies A, Ravaris L, et al. Clinical pharmacology ot phenelzine. Arch Gen Psychiatry 1978, 35: 629-35
116. Roper Reports. Report to Medicaid: what people do for minor health problems. New York: Roper Organization, 1986: 86-8.
117. Johnson DAW. Non-compliance with antidepressant therapy: an underestimated problem. Intern Med 1986; 11 Suppl.: 14-7
118. Waters WH, Gould NV, Lunn JE. Undispenscd prescriptions in a mining general practice. BMJ 1976: 1: 1062-3
119. Begg D. Do patients cash prescriptions? An audit in one practice. J R Coll Gen Pract 1984; 34: 272-4
120. Rashid A. Do patients cash prescriptions? BMJ 1982; 284: 24-6
121. Beardon PH, McGilchrist MM, McKendrick AD, et al. Primary non-compliance with prescribed medication in primary care. BMJ 1993; 307: 846-8
122. Murray J, Shepherd S. Alternative or additional medicine? A new dilemma for the doctor. J R Coll Gen Pract 1988; 38: 511-4
123. Corney RH. Marital problems and treatment outcome in depressed women: a clinical trial of social work intervention. Br J Psychiatry 1987; 151: 652-9
124. Freeling P, Harris CM. The doctor/patient relationship. London: Churchill Livingstone, 1984
125. Hawton K. Controlled studies of psychosocial intervention following attempted suicide. In: Kreitman N, Platt S, editors. Current research on suicide and parasuicide. Edinburgh: Edinburgh University Press, 1989
126. Rosenberg NK. Psychotherapy ot the suicidal patient. Acta Psychiatr Scand 1993; 371 Suppl.: 54-6
127. Elkin I, Shea MT, Watkins JT, et al. National Institute of Mental Health treatment of depression collaborative research program: general effectiveness of treatments. Arch Gen Psychiatry 1989; 46: 971-82
128. Paykel ES, Dirlascio A, Haskell D, et al. Effects of maintenance amitriplyline and psychotherapy on symptoms of depression. Psychol Med 1975; 5: 67-77
129. Sturm R, Wells KB. How can care for depression become more cost-effective? JAMA 1995; 273: 51-8
130. Blackburne IM, Bishop S, Glen IM, et al. The efficacy of cognitive treatment in depression: a treatment trial using cognitive therapy and pharmacotherapy, each alone and in combination. Br J Psychiatry 1981; 139: 181-9
131. Teasdale JD, Fennell MJV, Hibbert GA. et al. Cognitive therapy for major depressive disorders in primary care. Br J Psychiatry 1984; 144: 400-6
132. Rush AJ, Beck AT, Kovacs M, et al. Comparative efficacy of cognitive therapy and pharmacotherapy in the treatment of depressed outpatients. Cognit Ther Res 1977; 1: 17-37
133. Frank E, Kupfer DJ, Perel JM, et al. Three-year outcomes, for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990; 47: 1093-9
134. Agency of Health Care Policy and Research - Depression Guideline Panel. Depression in Primary Care, vol. 2. Treatment of major depression. Clinical practice guideline 5. Rockville (MD): US Dept of Health and Human Services, 1993; ACHPR Publication 93-0551
135. Avery D, Winokur G. The efficacy of electroconvulsive therapy and antidepressants in depression. Biol Psychiatry 1977; 12: 507-23
136. Sack DA, Nurnberger J, Rosenthal NE, et al. The potentiation of antidepressant medications by phase advance of the sleep-wake cycle. Am J Psychiatry 1985; 142: 606-8
137. Schligen B, Tolle R. Partial sleep deprivation as therapy for depression. Arch Gen Psychiatry 1980; 37: 267-71
138. Glaser WA, The politics of paying physicians. Health Aff 1989; 8: 129-46
139. Jonsson B. The pharmaceutical market. In: Bourdet, editor. Internationalisation, market power and consumer welfare. London: Routledge, 1992
140. Association of the British Pharmaceutical Industry. Pharma Facts and Figures. London: ABPI, 1992
141. European Federation of Pharmaceutical Industries' Associations. The pharmaceutical industry in Europe 1990-1991. EFPIA, 1992
142. Coney S. NZ's Pharmac tackles antidepressant bill. Lancet 1994; 344; 463-4
143. McLeod AJ. Rational prescribing [letter]. BMJ 1994; 308: 1573
144. Drummond M, Torrance G, Mason J. Cost-effectiveness league tables: more harm than good? Soc Sci Med 1993; 37: 33-40
145. Rucker TD, Schiff G. Drug formularies: myths-in-formation. Med Care 1990; 28 (10): 928-42
146. Shepherd MD, Salzman RD. The formulary decision-making process in a health maintenance organisation setting. Pharmacoeconomics 1994; 5 (1): 29-38
147. Bochner F, Martin DE, Burgess NG, et al. Drug rationing in a teaching hospital: a method to assign priorities. BMJ 1994; 308: 901-5
148. Donaldson C. Formulate, don't formularise. BMJ 1994; 308: 905-6
149. Petrie JC. First consider the overall process of care [letter]. BMJ 1994; 308: 906
150. Chadwick R. Fairness is at issue [letter]. BMJ 1994; 308: 907-8
151. Drummond MF. The economics of drug formularies. Pharm J 1989; 15: 451-2
152. Hanson HS, Shepherd MD, Pleil A, et al. How P&T committee members in HMSOs make formulary decisions. PT 1992; 17: 247-54
153. Taylor S, McLean P. Outcome profiles in the treatment of unipolar depression. Behav Res Ther 1992; 31 (3): 325-30
154. Henry JA, Alexander CA, Sener EK. Relative mortality from overdose of antidepressants. BMJ 1995; 310: 221-4
155. Montgomery SA, Henry JA, McDonald G, et al. Selective serotonin reuptakc inhibitors: meta-analysis of discontinuation rates. Int Clin Psychopharmacol 1994; 9: 47-54
156. Sloan FA, Gordon GS, Cocks DL. Hospital drug formularies and use of hospital services. Med Care 1993; 31 (10): 851-67
157. Pearce MJ, Begg KJ. A review of limited lists and formularies. Pharmacoeconomics 1992; 1(3): 191-202
158. Hazlet TK, Hu TW. Association between formulary strategies and hospital drug expenditure. Am J Hosp Pharm 1992; 49 (9): 2207-10
159. Scrip 26 Mar 1996
160. Raisch DW. Relationship among prescription payment methods and interactions between community pharmacists and prescribers. Ann Pharmacother 1992; 26 (7-8): 902-6
161. Goldberg D. Gater R. Estimates of need. Psychiatr Bull 1991; 15: 593-5
162. Thompson C, Thompson CM. The prescription of antidepressants in general practice: a critical review. Hum Psychopharmacol 1989; 4: 91-102
163. Bradlow J, Coulter A. Effect of fundholding and indicative prescribing schemes on general practitioners' prescribing costs. BMJ 1993; 307: 1186-9
164. Bligh J, Walley T. The UK Indicative Prescribing Scheme. Pharmacoeconomics 1992; 2 (2): 137-52
165. Bradley C. Decision making and prescribing patterns: a literature review. Fam Prac 1991; 8 (3): 276-87
166. Avorn J, Soumerai SB. Improving drug-therapy decisions through educational outreach: a randomized control trial of academically based 'detailing'. N Engl J Med 1983; 308: 1457-63
167. Gehlbach SH, Wilkinson WE, Hammond WE, et al. Improving drug prescribing in a primary care practice. Med Care 1984; 22: 193-201
168. Harris CM, Jarman B, Woodman E, et al. Prescribing: a case for treatment. London: Royal College of General Practitioners, 1984: occasional paper no. 24
169. Hux JE, Naylor CD. Drug prices and third party payment: do they influence medical selection? Pharmacoeconomics 1994; 5 (4): 343-50
170. Jabbari B, Bryan GE, Marsh EE, et al. Incidence of seizures with tricyclic and tetracyclic antidepressants. Arch Neurol 1985; 42 (5): 480-1
171. Hale AS. New antidepressants: use in high-risk patients. J Clin Psychiatry 1993, 54 (8 Suppl.): 61-70
172. Overall JE. Efficacy of nomifensine in different depressive syndromes. J Clin Psychiatry 1984; 45 (4): 85-8
173. Boyer WF. Potential indications for the SSRIs. Int Clin Psychopharmacol 1992; 53: 61-6
174. Wakelin JS, Coleman BS. The influence of lhe 5-HT specific antidepressant, fluvoxamine maleate, on suicidal behaviour [abstract]. Int J Neurosci 1986; 31: 216
175. Mullin JM, Pandila-Gunawardena VR, Whitehead AM. A double-blind comparison of fluvoxamine and dothiepin in the treatment of major affective disorder. Br J Clin Prac 1988; 42 (2): 51-5
176. Sacchetti E, Vita A, Guarneri L et, al. The effectiveness of fluoxetine, clomipramine, nortriptyline and desipramine in major depressives with suicidal behaviour: preliminary findings. In: Casano GB, Akiskal HS, editors. Serotonin-related psychiatric syndromes: clinical and therapeutic links. London: Royal Society of Medicine, 1991 (International Congress and Symposium Series; 165)
177. Feldman HS, Denher HC. Long-term study of fluvoxamine: a new rapid-acting antidepressant. Int Pharmacopsychiatry 1982; 17: 114-22
178. Henry JA, Martin AJ. The risk-benefit assessment of antidepressant drugs. Med Toxicol 1987; 2: 445-62
179. Muijen M, Roy D, Silverstone T, et al. A comparative clinical trial of fluoxetine, mianserin and placebo with depressed outpatients. Acta Psychiatr Scand 1988; 78: 384-90
180. Wakelin J. The role of serotonin in depression and suicide. Adv Biol Psychiatry 1988; 17: 70-83
181. de Wilde JEM, Doogan DP. Fluvoxamine and clomipramine in endogenous depression. J Affec Disord 1982; 4: 249-59
182. Martin AJ, Tebbs VM, Ashford JJ. Affective disorders in general practice: treatment of 6000 patients with fluvoxamine. Pharmatherapeutica 1987; 5: 40-8
183. Montgomery SA, Pinder RM. Do some antidepressants promote suicide? Psychopharmacology 1987; 92: 265-6
184. Montgomery SA, McAulay R, Rani SJ. A double blind comparison of zimelidine and amitriptyline in endogenous depression. Acta Psychiatr Scand 1981; 63: 314-27
185. Damluji NF, Ferguson JM. Paradoxical worsening of depressive symptomatology caused by antidepressants. J Clin Psychopharmacol 1988; 8 (5): 347-9
186. Beasley CM, Dornseif BE, Bosomworth MES, et al. Fluoxetine and suicide: a meta-analysis of controlled trials of treatment of depression. BMJ 1991; 303: 665-92
187. Fava M, Rosenbaum JF. Suicidalily and fluoxetine - is there a relationship? J Clin Psychiatry 1991; 52: 108-11
188. Rouillon R, Philips R, Serrurier D, et al. Rechutes du depression unipolaire et efficacite de la maprotiline. L'Encephale 1993; XV: 527-34
189. Feuerstein TJ, Jakisch R. Why do some antidepressanls promote suicide [letter]? Psychopharmacol 1986; 90: 422
190. Doogan DP, Caillard V. Sertraline in the prevention of depression. Br J Psychiatry 1992; 160: 217-22
191. Wernicke JF, Bosomworth JC, Ashbrook E. Fluoxetine at 20 mg per day: the recommended and therapeutic dose in the treatment of depression. Int Clin Psychopharmacol 1989; 4 Suppl. 1: 63-7
192. Weissman MM. The epidemiology of suicide attempts, 1960-1971. Arch Gen Psychiatry 1974; 30: 737-46
193. Johnson DAW. Depression: treatment compliance in general practice. Acta Psychiatr Scand 1981; 63: 447-53
194. Johnson DAW. Antidepressant treatment observed: some problems of compliance by doctors and patients. In: Sims, Ottofson, editors. Antidepressants: progress in problem areas. London: Franklin Scientific Projects, 1984
195. Canino GJ, Bird HR, Shrout PE, et al. The prevalence of specific psychiatric disorders in Puerto Rico. Arch Gen Psychiatry 1987; 44 (8): 727-35
196. Blacker CVR, Clare AW. The prevalence and treatment of depression in general practice. Psychopharmacol 1988; 95: 14-17
197. Keller MB, Klerman GL Lavori PW, et al. Treatment received by depressed patients. JAMA 1982; 248 (15): 1848-55
198. Tyrer P. Drug treatment of psychiatric patients in general practice. BMJ 1978: 2: 1008-10
199. Kass F, Charles E, Walsh T, et al. Quality review of outpatient psychopharmacological practice with APA Task Force criteria. Am J Psychiatry 1983; 140 (2): 221-4
200. Fish D. What is an effective dose [letter]? BMJ 1997; 314: 826
201. Gill D. Systematic review of all pertinent trials is required to establish guidelines [letter]. BMJ 1997; 314: 826-7
202. Tan RS. Low dose tricyclic antidepressants are effective in treating major depression [letter]. BMJ 1997; 314: 827
203. Gorham PN. Who bears the cost of antidepressants in Australia? Med J Aust 1995; 162: 162-3
204. Maxwell M, Heaney D, Howie JGR, et al. General practice fundholding: observations on prescribing patterns and costs using the defined daily dose method. BMJ 1993; 307: 1190-4
205. Griffin JP, Griffin TD. The economic implications of therapeutic conservatism. J R Coll Physicians Lond 1993; 27 (2): 121-6
206. Goldstein AO, Ives TJ. Depression treatment. J Fam Pract 1994; 38: 49-57
207. Kind P, Sorensen J. Modelling the cost-effectiveness of the prophylactic use of SSRIs in the treatment of depression. Int Clin Psychopharmacol 1995; 10: 41-8
208. Le Pen C, Levy E, Ravily V, et al. The cost of treatment dropout in depression: a cost-benefit analysis of fluoxetine vs tricyclics. J Affect Disord 1994; 31: 1-18